Tirzepatide is a dual GIP/GLP-1 receptor agonist with a 5-day half-life, meaning it takes approximately 25 days (3-4 weeks) for the medication to be substantially eliminated from your body after your final injection
The most common patient complaints are minor: soreness at injection site, a transient headache, or mild diarrhea
For example, after two minutes, 50% of the GLP-1 released from the gut in response to a meal is removed from the blood
Until the underlying cause is confirmed, predicting who will get it is difficult
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management and chronic weight management
The decision between medical and surgical treatment depends on the diagnosis, patient preferences, and overall health status